SWOG clinical trial number
SWOG-9219
A Phase II Evaluation of Interleukin-4 (IL-4) in Patients with Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
49%
Published
Research committees
Lymphoma
Treatment
Interleukin-4
Eligibility Criteria Expand/Collapse
biopsy proven low, intermediate or high grade NHL; measurable disease; prior therapy is required as in protocol; no AIDS or HIV; no impaired cardiac status; no CNS involvement
Publication Information Expand/Collapse
2000
Phase II evaluation of interleukin-4 in patients with non-hodgkin's lymphoma: a Southwest Oncology Group trial
Other Clinical Trials
SWOG Clinical Trial Number
S2506
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
74%
Open
Phase